SCHEMBL4741835

SCHEMBL4741835

O=c1cc(O)nc(Cc2ccccc2)n1Cc1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.51
MEN1 O00255 6/20 0.49
KMT2A Q03164 6/20 0.49
SMN1; SMN2 Q16637 4/20 0.49
MAPT P10636 2/20 0.49
KDM4E B2RXH2 1/20 0.49
ALDH1A1 P00352 1/20 0.49
GSK3B P49841 1/20 0.48
TP53 P04637 4/20 0.47
MDM2 Q00987 1/20 0.47
TDP1 Q9NUW8 1/20 0.46
HTT P42858 1/20 0.45
GPR35 Q9HC97 1/20 0.43
ATM Q13315 1/20 0.43
CCR2 P41597 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
HPGD P15428 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4738614 0.93 GSK3B (0.46) LMNAMEN1KMT2ASMN1; SMN2MAPT
SCHEMBL4739999 0.92 LMNA (0.45) LMNAMEN1KMT2ASMN1; SMN2MAPT
SCHEMBL4739125 0.84 GSK3B (0.51) LMNAMEN1KMT2ASMN1; SMN2MAPT
SCHEMBL3521617 0.80 ALDH1A1 (0.51) LMNAMEN1KMT2ASMN1; SMN2MAPT
SCHEMBL4737051 0.79 BCL2 (0.55) LMNAMEN1KMT2ASMN1; SMN2MAPT
SCHEMBL4739122 0.77 KMT2A (0.47) MEN1KMT2ASMN1; SMN2MAPTKDM4E
SCHEMBL4737871 0.76 GSK3B (0.42) LMNAMEN1KMT2ASMN1; SMN2MAPT
SCHEMBL4737869 0.76 ALDH1A1 (0.45) LMNAMEN1KMT2ASMN1; SMN2MAPT
SCHEMBL4784822 0.74 MEN1 (0.45) MEN1KMT2ASMN1; SMN2MAPTKDM4E
SCHEMBL4740165 0.74 KDM4E (0.48) LMNAMEN1KMT2ASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008089051-A1 N-SUBSTITUTED GLYCINE DERIVATIVES: PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-07-24 WO disclosed
US-20080171756-A1 N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2008-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080171756-A1 N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors HIF1AN, EGLN2, EGLN3 LMNA 3270/4885MEN1 2935/4885KMT2A 734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.